November 7, 2019 11:10 AM EST
R&D

De­clar­ing topline PhI­II win, Take­da re­vives block­buster hopes for its trou­bled mul­ti­ple myelo­ma drug

Jason Mast

Editor

Five months af­ter dis­mal tri­al re­sults con­vinced Take­da to scrap an en­tire Phase III pro­gram for their mul­ti­ple myelo­ma drug Nin­laro, the Japan­ese gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times